29https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&WebEnv=MCID_600afc5a9a76eb6ec571f0be&query_key=1&retmode=xml&retstart=0&retmax=20&tool=PubFacts&email=info@pubfacts.com&api_key=cff79fa78dbf3b485398a7005ab1d5a49508 Thomas C Harding | PubFacts

Publications by authors named "Thomas C Harding"


A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.

Cell Rep 2018 Apr;23(3):918-929

Bioengineering and Therapeutic Sciences, Helen Diller Family Comprehensive Cancer Center and Institute for Computational Health Sciences. University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article and Find Full Text PDF
April 2018

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Cancer Discov 2013 Dec 24;3(12):1404-15. Epub 2013 Sep 24.

1Clovis Oncology Inc., San Francisco, California; 2Celgene Avilomics Research, Bedford, Massachusetts; 3Division of Hematology-Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; 4Mouse Cancer Genetics Program; and 5Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, Maryland.

View Article and Find Full Text PDF
December 2013

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

Mol Ther 2007 Jun 20;15(6):1153-9. Epub 2007 Mar 20.

Department of Preclinical Oncology and Immunology, Cell Genesys, Inc., South San Francisco, California 94080, USA.

View Article and Find Full Text PDF
June 2007